Ancestry-based pharmacogenomics, adverse reactions and carbamazepine: is the FDA warning correct?
Ancestry-based pharmacogenomics, adverse reactions and carbamazepine: is the FDA warning correct?
复制标题
DOI：
10.1038/tpj.2014.14
复制
发表时间：
2014-10-01
影响因子：
2.8
通讯作者：
Payne, P. W.
中科院分区：
文献类型：
--
作者：
Payne, P. W.
In an effort to prevent potentially fatal adverse reactions to carbamazepine, the US Food and Drug Administration (FDA) issued an alert in 2007 containing pharmacogenomic information, which is still in effect today. The alert states that carbamazepine-induced skin reactions are significantly more common in patients with the human leukocyte antigen (HLA)-B*1502 allele and that these people are almost exclusively from 'broad areas of Asia, including South Asian Indians.' This study reviews the medical evidence relied upon by the FDA and finds that the alert does not accurately reflect the medical evidence relied upon in 2007 or evidence that has been generated over the last 5 years since the label was created. The FDA drug labeling should be modified to reflect current medical evidence.
